title: [Drug treatment for the treatment of primary osteoporosis].
abstract: The goal of drug treatment of osteoporosis is to prevent fractures. Increase of bone density during therapy is not consistently associated with a clinical benefit. The purpose of this paper is to review the evidence of fracture prevention from published randomized controlled trials. Vitamin D, the bisphosphonate alendronate and the selective estrogen receptor modulator raloxifene have been evaluated in large randomized trials with clinical endpoints.
authors.affiliation: ati@berlin.snafu.de
authors.forename: J
authors.initials: J
authors.lastname: Halbekath
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D005459:Fluorides / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D020845:Selective Estrogen Receptor Modulators; D014807:Vitamin D; D020849:Raloxifene Hydrochloride; D005459:Fluorides; D019386:Alendronate